GlycoMimetics Inc (GLYC) News

Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024

Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024 PR Newswire WALTHAM, Mass., Nov...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that data from multiple clinical trials studying uproleselan in patients with acute myeloid...

Form SC 13D - General Statement of Acquisition of Beneficial Ownership

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Shares of Biotech Company Up Over 100% Premarket Following Merger & Funding Announcement

A Maryland-based biotech company is already dominating Tuesday’s session prior to the opening bell after it was announced that the company...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

Following closing, the combined company will advance Crescent’s portfolio of precision-engineered biologics to improve outcomes for patients with...

GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint

GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors